Recon: FDA places clinical hold on Neumora’s schizophrenia drug trial; WHO issues warning after falsified cough syrup ingredients seized in Pakistan

• Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle (STAT)
• FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits (Endpoints)
• Adcomm backs use of minimal residual disease in multiple myeloma accelerated approvals (Endpoints)
• FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs (Fierce Pharma)
• The top 20 pharma companies by 2023 revenue (Fierce Pharma)
• Eisai on your hi-fi: Leqembi maker supports creation of Alzheimer's podcast miniseries (Fierce Pharma)
• Ivermectin Settlement Brings Relief And Worry For US FDA Communications (Pink Sheet)

• WHO warns of falsified cough syrup ingredients seized in Pakistan (Reuters)
• Tanzania, Rwanda, Zimbabwe join African recall of J&J cough syrup (Reuters)
• Lady Gaga's Instagram post about latest Pfizer Nurtec ODT ad earns EU ire: Politico (Fierce Pharma)
• EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions (Pink Sheet)
• UK Industry Gets More Time To Adapt To Post-Brexit Import Rules (Pink Sheet)
• Estonian Biobank’s Personalized Medicine Project To Unlock New Insights For Drug R&D (Pink Sheet)
• More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm (Reuters)

• When a cancer drug fails, oncologists often fly blind. A precision technique might light the way (STAT)
• Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition (STAT)
• Novavax investor Shah Capital pushes for board shakeup (Reuters)
• Organovo's drug significantly reduces liver fat in NASH study (Reuters)
• Regeneron enters venture investing with $500M, poaches senior partner from ARCH (Endpoints)
• Roche’s Columvi passes Phase 3 lymphoma test as competition with AbbVie, Genmab continues (Endpoints)
• Astellas writes down another piece of its Audentes gene therapy acquisition (Endpoints)
• Vertex's $4.9B bet; Layoffs at Novartis, Genentech, Sanofi; Star founders unveil new startups; and more (Endpoints)
• AstraZeneca cries havoc over CKD's hit on economies, environment (Fierce Pharma)
• Gilead enlists Grammy nominee Raheem DeVaughn in HIV education, prevention initiative (Fierce Pharma)
• Castle Biosciences fortifies support of Esophageal Cancer Awareness Month with fundraising, educational collabs (Fierce Pharma)

• Exclusive: Eating disorder telehealth startup Equip raises $35M, according to filing (Endpoints)
• Abbott’s Nadim Geloo on Triclip’s US launch, Edwards competition (MedTech Dive)
• Roche scores FDA breakthrough status for Alzheimer’s blood test (MedTech Dive)
• Osso VR brings surgery training app to Apple Vision Pro (MedTech Dive)

• Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more (STAT)
• Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps (STAT)
• Mass General Brigham is ready to move on without Dana-Farber, CEO says (STAT)
• ADHD is often overlooked in females. They need help, too (STAT)
• Hospitals that make profits should pay taxes (STAT)
• Exclusive: Health insurance broker GoHealth trims jobs across departments (Endpoints)